273 related articles for article (PubMed ID: 21072502)
1. Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues.
Schifano F; Albanese A; Fergus S; Stair JL; Deluca P; Corazza O; Davey Z; Corkery J; Siemann H; Scherbaum N; Farre' M; Torrens M; Demetrovics Z; Ghodse AH; ;
Psychopharmacology (Berl); 2011 Apr; 214(3):593-602. PubMed ID: 21072502
[TBL] [Abstract][Full Text] [Related]
2. Mephedrone (4-methylmethcathinone, 'meow'): acute behavioural effects and distribution of Fos expression in adolescent rats.
Motbey CP; Hunt GE; Bowen MT; Artiss S; McGregor IS
Addict Biol; 2012 Mar; 17(2):409-22. PubMed ID: 21995495
[TBL] [Abstract][Full Text] [Related]
3. The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone).
Dargan PI; Sedefov R; Gallegos A; Wood DM
Drug Test Anal; 2011; 3(7-8):454-63. PubMed ID: 21755604
[TBL] [Abstract][Full Text] [Related]
4. Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, "meow meow") in the United Kingdom.
Schifano F; Corkery J; Ghodse AH
J Clin Psychopharmacol; 2012 Oct; 32(5):710-4. PubMed ID: 22926609
[TBL] [Abstract][Full Text] [Related]
5. Dependence and psychosis with 4-methylmethcathinone (mephedrone) use.
Bajaj N; Mullen D; Wylie S
BMJ Case Rep; 2010 Nov; 2010():. PubMed ID: 22791836
[TBL] [Abstract][Full Text] [Related]
6. [Mephedrone].
Bertrand X; Gensburger M; Steckx E
Rev Med Liege; 2011 Oct; 66(10):540-4. PubMed ID: 22141261
[TBL] [Abstract][Full Text] [Related]
7. Mephedrone (4-methylmethcathinone): what is new in our understanding of its use and toxicity.
Wood DM; Dargan PI
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):227-33. PubMed ID: 22564711
[TBL] [Abstract][Full Text] [Related]
8. [Mephedrone: a designer drug of recent use in France].
Debruyne D; Courné MA; Le Boisselier R; Djezzar S; Gérardin M; Boucher A; Karila L; Coquerel A; Mallaret M
Therapie; 2010; 65(6):519-24. PubMed ID: 21176758
[TBL] [Abstract][Full Text] [Related]
9. Mephedrone, new kid for the chop?
Winstock AR; Mitcheson LR; Deluca P; Davey Z; Corazza O; Schifano F
Addiction; 2011 Jan; 106(1):154-61. PubMed ID: 20735367
[TBL] [Abstract][Full Text] [Related]
10. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse.
Hadlock GC; Webb KM; McFadden LM; Chu PW; Ellis JD; Allen SC; Andrenyak DM; Vieira-Brock PL; German CL; Conrad KM; Hoonakker AJ; Gibb JW; Wilkins DG; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2011 Nov; 339(2):530-6. PubMed ID: 21810934
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacology of the Synthetic Cathinone Mephedrone.
Papaseit E; Moltó J; Muga R; Torrens M; de la Torre R; Farré M
Curr Top Behav Neurosci; 2017; 32():313-331. PubMed ID: 28012094
[TBL] [Abstract][Full Text] [Related]
12. [Mephedrone, the new designer drug of abuse: pharmacokinetics, pharmacodynamics and clinical and forensic issues].
Ribeiro E; Magalhães T; Dinis-Oliveira RJ
Acta Med Port; 2012; 25(2):111-7. PubMed ID: 22985922
[TBL] [Abstract][Full Text] [Related]
13. The psychoactive drug of abuse mephedrone differentially disrupts blood-brain barrier properties.
Buzhdygan TP; Rodrigues CR; McGary HM; Khan JA; Andrews AM; Rawls SM; Ramirez SH
J Neuroinflammation; 2021 Mar; 18(1):63. PubMed ID: 33648543
[TBL] [Abstract][Full Text] [Related]
14. Mephedrone: Public health risk, mechanisms of action, and behavioral effects.
Dybdal-Hargreaves NF; Holder ND; Ottoson PE; Sweeney MD; Williams T
Eur J Pharmacol; 2013 Aug; 714(1-3):32-40. PubMed ID: 23764466
[TBL] [Abstract][Full Text] [Related]
15. Deaths of individuals aged 16-24 years in the UK after using mephedrone.
Loi B; Corkery JM; Claridge H; Goodair C; Chiappini S; Gimeno Clemente C; Schifano F
Hum Psychopharmacol; 2015 Jul; 30(4):225-32. PubMed ID: 26216555
[TBL] [Abstract][Full Text] [Related]
16. Substitutional potential of mephedrone: an analysis of the subjective effects.
Kapitány-Fövény M; Kertész M; Winstock A; Deluca P; Corazza O; Farkas J; Zacher G; Urbán R; Demetrovics Z
Hum Psychopharmacol; 2013 Jul; 28(4):308-16. PubMed ID: 23881878
[TBL] [Abstract][Full Text] [Related]
17. The novel psychoactive substance 3-methylmethcathinone (3-MMC or metaphedrone): A review.
Ferreira B; Dias da Silva D; Carvalho F; de Lourdes Bastos M; Carmo H
Forensic Sci Int; 2019 Feb; 295():54-63. PubMed ID: 30572220
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of mephedrone analogs and related new psychoactive substances.
Luethi D; Kolaczynska KE; Docci L; Krähenbühl S; Hoener MC; Liechti ME
Neuropharmacology; 2018 May; 134(Pt A):4-12. PubMed ID: 28755886
[TBL] [Abstract][Full Text] [Related]
19. Mephedrone related fatalities: a review.
Busardò FP; Kyriakou C; Napoletano S; Marinelli E; Zaami S
Eur Rev Med Pharmacol Sci; 2015 Oct; 19(19):3777-90. PubMed ID: 26502870
[TBL] [Abstract][Full Text] [Related]
20. Instability of the ecstasy market and a new kid on the block: mephedrone.
Brunt TM; Poortman A; Niesink RJ; van den Brink W
J Psychopharmacol; 2011 Nov; 25(11):1543-7. PubMed ID: 20826554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
